Please login to the form below

Not currently logged in
Email:
Password:

BMS/Ono enter extended agreement

Bristol-Myers Squibb and Ono Pharmaceutical have announced an agreement to develop separate therapies for cancer and rheumatoid arthritis

Bristol-Myers Squibb (BMS) and Ono Pharmaceutical have announced an agreement to develop separate therapies for cancer and rheumatoid arthritis.

The agreement involving anti-PD-1 antibody known as BMS-936558/ONO-4538 consists of the expansion of BMS' territorial rights to develop and commercialise it. The drug is an investigational cancer immunotherapy which was created under a collaboration in May 2005 between Ono and Medarex.

When Medarex was acquired by BMS, it also gained the rights to develop and commercialise the anti-PD-1 antibody in North America. These rights have now been extended allowing BMS to develop and commercialise the drug around the world, except in Japan, Korea and Taiwan, where Ono has retained all rights.

The other agreement created is for the co-development and co-commercialisation of Orencia (abatacept) in Japan. The drug is a biologic therapy for the autoimmune disease rheumatoid arthritis, and is indicated for use in patients for whom other therapies have failed.

The agreement covers both the currently approved intravenous (IV) formulation and the subcutaneous (SC) formulation, as well as includes all current and future indications. Bristol-Myers K.K. (BMS's Japanese subsidiary) will distribute and book sales of Orencia IV. Ono will distribute and book the sales of Orencia SC.

21st September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics